Search: Look for:   Last 1 Month   Last 6 Months   All time

Just one dose of new malaria drug twice as effective as existing medicine

Washington, Thu, 18 Oct 2012 ANI

Washington, October 18 (ANI): Scientists have developed a new malaria drug that, in laboratory tests, has been twice as effective as the best current medicine against this global scourge.

And it may fight off the disease with just one dose, instead of the multiple doses that people often fail to take.

Gary Posner and colleagues explain that malaria continues to kill almost 1 million people annually. The best existing treatment is so-called artemisinin combination therapy (ACT).

It requires patients to take pills every day for several days, and many patients fail to complete the regimen. As a result, these patients don't get better, and it opens the door for malaria parasites to develop resistance to ACT.

To stop that from happening, the researchers developed a new type of ACT that could stop malaria in a single dose.

They describe a series of new compounds they developed that, given once, are more effective than traditional artemisinin-derived substances. One of the new compounds, when combined with mefloquine, killed off all of the parasites in some mice with just a single oral dose and allowed those mice to live almost twice as long as those treated with conventional ACT.

The new drug was described in ACS' Journal of Medicinal Chemistry. (ANI)


LATEST IMAGES
Manohar Lal being presented with a memento
Manoj Tiwari BJP Relief meets the family members of late Ankit Sharma
Haryana CM Manohar Lal congratulate former Deputy PM Lal Krishna Advani on his 92nd birthday
King of Bhutan, the Bhutan Queen and Crown Prince meeting the PM Modi
PM Narendra Modi welcomes the King of Bhutan
Post comments:
Your Name (*) :
Your Email :
Your Phone :
Your Comment (*):
  Reload Image
 
 

Comments:


 

OTHER TOP STORIES


Excellent Hair Fall Treatment
Careers | Privacy Policy | Feedback | About Us | Contact Us | | Latest News
Copyright © 2015 NEWS TRACK India All rights reserved.